Rapha Capital Management

Rapha Capital Management investment thesis

Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities Learn More About Rapha Capital The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities. Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value. View Our Portfolio Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII. Poseida Therapeutics, Inc. NexImmune, Inc. View Exit History Rapha Capital Lates

Rapha Capital Management team (1)

Partners and principals at Rapha Capital Management:

• Kevin Slawin — sweet spot $100K

Rapha Capital Management portfolio companies

Companies listed on Rapha Capital Management's public materials include: Skip to main content, Leadership, Exit History, Poseida Therapeutics, Inc., NexImmune, Inc., Disclaimer, Portfolio, AsclepiX Therapeutics, Bellicum Pharmaceuticals, DELiver Therapeutics, Eos SENOLYTIX, FIZE Medical, Ltd, IMAGIN Medical, K2 Biolabs, NuMat Technologies, Inc., Perseus SENOLYTIX, Phoenix SENOLYTIX, Ponce Aurora, PrintBio, SENOTHERAPEUTIX, Sightly Enterprises, Inc., Rapha Entities, Media Center, News & Press, Events & Presentations, Investor Login, Rapha Capital BioVentures Fund I, Arbor Rapha Spac, [email protected], Visit Website, egalli, Asclepix Therapeutics, Inc., Read Article, Dan Tetzl, Baltimore-based AsclepiX Therapeutics raises $5M.

Is Rapha Capital Management a fit for your round?

Upload your pitch deck and see whether anyone at Rapha Capital Management appears in your top matches.